BioPorto has received notification from Siemens Diagnostics of a communication to their international subsidiaries putting a halt to sales activities concerning The NGAL TestTM. Siemens will refer interested customers to BioPorto. BioPorto is now looking further into the reasons for this and the prospects for activities being resumed.
On December 10, 2012, Siemens Diagnostics issued a marketing letter to their international subsidiaries on the sales cooperation with BioPorto, as described in company announcement no. 23 dated November 29, 2012.
Thea Olesen, CEO
Christina Thomsen, Investor Relations
Tel. +45 45 29 00 00, e-mail email@example.com